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Abstract
Background. Hyaluronan (HA) is a component of the extracellular matrix in lung tissue and is normally present at low
concentrations in blood. HA is rapidly cleared from blood by the liver. Increased concentrations of plasmaHA have been found
in patients with acute respiratory distress syndrome (ARDS). We investigated changes in HA levels in plasma, bronchoalveolar
lavage ﬂuid (BALF), and lung, and their relationship to pretreatment with a leukocyte elastase inhibitor in a rat model
of ARDS.
Methods. Rats were randomly assigned to three groups: control, thrombin, and thrombin plus elastase inhibitor. By use of a
radiometric assay, HA was measured in lungs, BALF, and plasma. Tissue samples from the lungs were stained for HA and
examined microscopically. Liver circulation and cardiac output were monitored using radiolabeled microspheres.
Results. Infusion of thrombin produced a pronounced increase in wet weight to dry weight ratio, and relative lung water
content. This increase was blunted by a leukocyte elastase inhibitor. A decrease in lung HA and increases in both BALF and
plasma HA were found. The leukocyte elastase inhibitor counteracted not only the decrease in lung tissue HA, but also the
increase in plasma HA. Histologically, there was decreased HA-staining of peribronchial and perivascular areas in the injured
rat lung. Decreased liver perfusion was observed after infusion of thrombin.
Conclusions. The decrease in lung HA may be involved in the development of pulmonary edema in this ARDS model, and
leukocyte elastase may be one cause of this decrease. In addition, an elevated plasma HA level may be an indicator of lung
injury.
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Introduction
Hyaluronan (hyaluronic acid, HA) is an important
component of the extracellular matrix and is widely
distributed in the lung parenchyma in both man and
rat. HA has been shown to produce distinct biological
effects depending on the molecular weight (MW). HA
exists predominantly in a high-MW form (HMW-
HA; > 500 kDa) under physiological conditions (1).
Per se or in conjunction with collagen ﬁbers, proteo-
glycans, and other macromolecular elements of the
extracellular matrix, HA provides cellular support and
stabilization of structures and regulates cell–cell
adhesion and the movement of interstitial ﬂuid and
macromolecules in the lung (2,3). In contrast, a low-
molecular-weight HA (LMW-HA; < 500 kDa) can
function as an intracellular signaling molecule in
inﬂammation and has been found to be pro-inﬂam-
matory (4). The concentration of HA in the inter-
stitium is the result of a dynamic process of
equilibrium between biosynthesis and degradation,
inﬂuencing serum and tissue HA levels. However,
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this balance is altered in many diseases. Increased
deposition of HA in lung tissue has been observed
in bleomycin-injured rats (5), in a rat model
of monocrotaline-induced pulmonary hypertension
(6), acute respiratory distress syndrome (ARDS)
in man (7), premature monkeys (8), and oxygen-
induced lung injury in rabbit pups (9), whereas
increased HA synthesis has been reported in non-
human primates with ARDS (10). A decrease in lung
HA has been reported in group B streptococcal pneu-
monia in neonatal piglets (11) and was observed
10 days after monocrotaline-induced injury in rats,
before the onset of pulmonary hypertension (6). HA
was not elevated in lavaged lung tissue in radiation-
induced lung disease in rats (12).
Experimental studies have demonstrated a link
between the interstitial accumulation of HA and pul-
monary edema in bleomycin-induced alveolar injury
in the rat (5). Serum HA has been suggested as a
prognostic factor in patients with ARDS (13). How-
ever, the mechanisms responsible for these HA abnor-
malities are poorly understood.
Thrombin-induced lung injury, an animal model of
ARDS, is characterized by increased pulmonary vas-
cular permeability to protein, leading to severe pul-
monary edema (14). The pathophysiology of this
injury may involve leukocytes (15) and leukocyte
elastase (14). Reactive oxygen species and myeloper-
oxidase derived from stimulated polymorphonuclear
leukocytes are able to degrade HA directly (16,17).
Leukocyte elastase from activated neutrophils may
cleave extracellular matrix (ECM) components such
as proteoglycans, collagen, and ﬁbrin that are bound
to HA (18). Thus, HA bound to the ECM may be
released and subjected to oxygen-induced attacks. It
is therefore possible that the lung injury in this model
may lead to local degradation of HA.
We hypothesized that lung HA might be decreased
in rats with thrombin-induced lung injury due to an
increased wash-out of HA. Furthermore, we pro-
posed that the lung injury might be accompanied
by elevated concentrations of circulating HA
and that this elevation might be partly due to a
decreased uptake of HA in the liver, as a result of
diminished liver perfusion.
We therefore measured concentrations of HA in
lung tissue, bronchoalveolar lavage ﬂuid (BALF),
and plasma and studied lung tissue microscopically
for the presence of HA in rats with thrombin-
induced lung injury. We also investigated the effect
of a synthetic human leukocyte elastase inhibitor on
the levels of HA in thrombin-induced pulmonary
edema. In addition, we studied cardiac output and
liver circulation, since the liver plays an important
role in HA degradation.
Material and methods
Animals
Eighty-nine male Sprague-Dawley rats (Alab, Stock-
holm, Sweden) were used in this study. Seventy-
ﬁve of them were used for determination of HA
and divided into three treatment groups: control
(n = 24), thrombin (n = 40), and elastase inhibitor
plus thrombin (n = 11). All specimens for HA deter-
mination used in this study were obtained from our
previous studies. In separate experiments, cardiac
output was measured at intervals in six rats, and liver
blood ﬂow was determined in eight other rats given
thrombin; each rat being its own control. All rats
weighed between 200 and 250 g and had free access
to food (Ewos rat pellet) and tap water. The present
study was approved by the ethics committee at
Uppsala University.
Materials
Bovine thrombin (Topostasine, Hoffman La Roche,
Switzerland) was dissolved in physiological saline
(100 IU/mL), and kept at –20C until used. The
ﬁbrinolytic inhibitor tranexamic acid (trans-4-amino-
methyl-cyclo-hexane-carboxylic acid, AMCA, Kabi
Pharmacia, Stockholm, Sweden) was dissolved in
physiological saline (80 mg/mL).
Thiobutabarbital (Inactin) was supplied by
Sigma-Aldrich, Copenhagen, Denmark. The elastase
inhibitor, ICI 200,355 [4-(4-bromophenylsulfonyl-
carbamoyl)-benzoyl-L-valyl-L-proline 1(RS)-(1-tri-
ﬂuoroacetyl-2-methylpropyl)amide] was supplied by
ICI Americas Inc., Wilmington, DE, USA. It is a
substituted triﬂuoromethylketone with a molecular
weight of 731.57 g/mol and an inhibition constant
versus human leukocyte elastase of 0.5 nM.
Vectastain reagent was supplied by Vector labora-
tories Inc., Burlingham, CA, USA and Streptomyces
hyaluronidase by Seikagaku Fine Biochemicals,
Tokyo, Japan. Bovine serum albumin, iodoacetic
acid, amino-n-caproic acid, benzamidine, and pep-
statin A were supplied by Sigma Chemical Co., St
Louis. MO, USA. Ethylene-diamine tetraacetic acid
(EDTA) was supplied by Merck, Darmstadt,
Germany and soy bean trypsin inhibitors by
Worthington, Freehold, NJ, USA.
Animal preparation
Rats were anesthetized intraperitoneally with
125 mg/kg of inactin, placed in a supine position
and tracheostomized. A tracheal cannula (PE 240,
Clay Adams, Becton Dickinson & Co., USA) was
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inserted for airway support, and an abdominal can-
nula (Portex; outer diameter 0.80 mm, Hythe, Kent,
England) was inserted into the peritoneal cavity for
AMCA injection and maintenance of anesthesia. All
rats breathed spontaneously through the tracheostomy,
and body temperature was maintained at 38C with an
electric pad. An intravenous injection site was prepared
in both saphenous veins using polyethylene catheters
(Portex; outer diameter 0.80 mm, Hythe, Kent, Eng-
land) and 26-gauge needles to inject the elastase inhib-
itor and thrombin. The elastase inhibitor was dissolved
in 4 mL of 0.1 M Na-phosphate buffer (pH 8.0) and
diluted with phosphate-buffered saline (PBS) (40 mg/
mL). The elastase inhibitor was then administered
continuously via the saphenous vein by an infusion
pump (B. Brown Apparatebau, Melsungen, Germany)
for approximately 2 h at a rate of 200 mg/kg h-1.
A catheter (PE 50, Clay Adams) inserted into
the right common carotid artery was advanced via
the aortic arch into the left ventricle for injection of
microspheres. Two other polyethylene catheters (PE
50, Clay Adams) were inserted and positioned into
the right and left femoral arteries for pressure record-
ings and withdrawal of reference blood samples,
respectively. The position of the catheter was con-
ﬁrmed by pressure tracing and post-mortem exami-
nation. A calibrated pump (model 355, Saga
Instrument, New York, USA) was used for determi-
nation of liver blood ﬂow and cardiac output.
Thrombin-induced lung injury was induced
according to the experimental protocol (Figure 1)
and as described previously (14). In brief, 15 min
before thrombin infusion, rats were injected through
the abdominal catheter with 200 mg/kg of AMCA to
prolong ﬁbrin entrapment in the lungs and increase
pulmonary damage (19); 500 NIH units/kg of bovine
thrombin were injected manually into the saphenous
vein over a period of 10 min, using a stop-watch and a
1.0 mL disposable syringe.
Rats were killed 90 min after the end of the throm-
bin infusion. The abdomen was opened, and the aorta
was gently freed to the level of the bifurcation of the
descending aorta. Aortic blood samples were drawn
into sodium citrate tubes from the aorta for determi-
nation of plasma HA, centrifuged at 400  g for
10 min, and kept at –20C until analyzed. The lungs
were excised, cleaned gently with gauze, weighed for
wet weight, and dried at 37C in a warm incubator for
approximately 72 hours. The lungs were reweighed
for dry weight until their weight was constant.
Wet weight to dry weight ratio and water content in the
lung tissue
The wet weight to dry weight ratio (WW/DW) was
determined in the left lung. The relative water content
was also calculated in the left lung as described
previously (5): the relative lung water content
(%) = [( WW–DW ) / WW]  100
Bronchoalveolar lavage
Bronchoalveolar lavage was performed by a previously
described method (20) with slight modiﬁcations. In
brief, animals were killed by aortic exsanguination
90 min after termination of the thrombin infusion.
The lungs were carefully dissected to the level of the
carina after removal of the heart. The left main stem
bronchus was tied proximally and then removed and
used for determination of the WW/DW. The right
Group –30 ~ 100 min - 15 min 0 ~ 10 min 100 min
Saline Saline Saline
Control Sacrifice
i.v infusion i.p iv infusion
Saline AMCA Thrombin
Thrombin 200 mg/kg 500 IU/kg Sacrifice
i.v infusion i.p iv infusion
Elastase
Inhibitor and
thrombin
Elastase inhibitor
200 µg/kg/h
i.v infusion 
AMCA
200 mg/kg
i.p
Saline
Sacrifice
iv infusion
Time schedule
Figure 1. Experimental protocol.
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lung was perfused in situ immediately after death by
intratracheal infusion of ﬁve 3-mL aliquots of PBS at
pH 7.4. Infusions were made under gravity at a
constant hydrostatic pressure below 20 cmH2O.
The lavage ﬂuid was kept in the lungs for 3 min
and recovered by gravity into 50 mL polystyrene tubes
on ice. The recovery was 13.9 mL of total 15 mL. The
lavage ﬂuid was centrifuged at 400 g for 10 min, and
the supernatant was kept frozen at –20C until
analyzed.
Extraction of lung tissue HA
The HA was extracted from the pulverized dried lung
with 0.5 MNaCl. The HA was also under dissociative
conditions, mixed with 4 M guanidinium chloride in
0.5 M sodium acetate buffer, pH 5.8, in order to
extract HA possibly aggregated with proteoglycans.
Twenty milligrams of the lungmaterial were extracted
with 2 mL of buffer for 16 hours under constant
shaking at 4C.
The samples were then centrifuged for 15 min at
2000  g. The supernatants were recovered and the
HA concentration determined. In order to destroy
any proteoglycan or link protein that might have
interfered with the HA assay, the guanidinium chlo-
ride extracts were treated with trypsin. The extract
was diluted with 10 volumes of 0.1 M Tris/
sodium acetate/HCl buffer, pH 7.3. Two units of
pronase (Pronas 200 units/mL, Boehringer,
Mannheim, Germany) were added, and the solution
was incubated overnight at 37C. The enzyme was
then heat-inactivated at 100C for 15 min. The HA
concentration in a reference sample of HA (1.0 mg/
mL) was not inﬂuenced by the enzymatic and heat
treatment.
Localization of HA in lung tissue
Staining for HA was performed by a previously
described technique (10) on sections that had been
ﬁxed in cetylpyridinium chloride buffered formalin
and embedded in parafﬁn; 3 mm sections were cut
from the base of the lung to the apex and put on
gelatin-coated slides, deparafﬁnized, and brought
through a graded alcohol series to water. The sections
were incubated ﬁrst with 3%H2O2 for 5 min and then
with bovine serum albumin, 10 mg/mL, for 30 min.
After washing (2  10 min) with PBS, pH 7.3,
sections were incubated overnight at 4C with HA
binding region from bovine nasal cartilage chondroi-
tin sulfate proteoglycan core protein (HABP)-biotin
(50 to 60 mg/mL). After two 10 min washes in PBS,
sections were incubated with Vectastain Elite ABC
Reagent for 30 min. After three further 10 min washes
in PBS, they were then incubated for 5 min in ethyl-
carbazole-DMSO.
Control sections were incubated for 2 h in a humid
chamber at 37C with 500 unit/mL of Streptomyces
hyaluronidase in 100 mM sodium acetate buffer, pH
5.8, in the presence of protease inhibitors, 1.8 mM
EDTA, 1.8mg/mL soy bean trypsin inhibitor, 2.0mM
iodoacetic acid, 0.18 mM amino-n-caproic acid,
9.0 mM benzamidine, and 1.8 mg/mL pepstatin A.
Sections were mounted under glass covers in Kaiser’s
glycerin-gelatin and examined by one observer with-
out knowledge of the experimental conditions of the
individual animals. Sections were then counterstained
with Mayer’s hematoxylin. Photographs were taken
using Normaski optics, on sections stained for HA
alone, and bright-ﬁeld microscopy was performed on
sections counterstained with hematoxylin. The spec-
iﬁcity of the reaction was checked by pretreatment of
sections with Streptomyces hyaluronidase.
Determination of HA
Concentrations of HA in plasma, BALF, and lung
tissue extracts were determined in duplicate with a
commercially available speciﬁc radiometric assay
(HA-50-test, Pharmacia Diagnostics, Uppsala,
Sweden), based on the use of speciﬁc HABP. HA
from the samples or HA-standards (100 mL) was
allowed to bind 125I-labeled HA binding region in
solution (200 mL) for at least 60 min at 4–22C. The
unbound 125I-labeled HA binding region was then
quantiﬁed after interaction with HA covalently bound
to Sepharose particles. Particles were separated by
centrifugation (1500  g) after decanting the suspen-
sion. Radioactivity bound to the particles was then
measured in a gamma counter. Sample concentra-
tions were read from a standard curve after plotting
percent radioactivity bound for standards against HA
concentration on a line-log paper. The detection limit
for HA was less than 5 mg/L, and variability of the
measurements of HA was less than 10%.
Determination of cardiac output and liver blood ﬂow
Cardiac output and liver blood ﬂow were measured as
described earlier (21). In brief, microspheres with a
diameter of 15 mm, labeled with 57Co, 85Sr, 95Nb,
46Sc, and 65Zn, were used. Each injection comprised
approximately 0.4  106 microspheres, suspended in
0.2 mL of homologous plasma. The microspheres
were thoroughly mixed on a vibrator and immediately
thereafter injected into the left ventricle during 15–
20 s. An arterial reference sample was drawn at a rate
of 0.49 mL/min using a calibrated pump, which was
started immediately before the microsphere injection
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was begun and continued until 90 s after its com-
mencement. For each microsphere injection, the type
of isotope was chosen randomly. The choice of iso-
tope did not inﬂuence blood ﬂow data. Cardiac out-
put and liver blood ﬂow were calculated by means of a
computer program (22).
Statistical analyses
Statistical signiﬁcances were tested by one-way anal-
ysis of variance amongst groups. A t test was used to
determine the statistical signiﬁcance of changes in HA
concentration in BALF between groups. Data are
expressed as means ± SEM.
Results
Biochemical variables
Administration of thrombin resulted in increased
WW/DW ratios and relative lung water content
(P < 0.001) (Table I). Thus, after infusion of throm-
bin, the WW/DW ratio increased by 42.3% and lung
water content by 7.0%. Pretreatment with the elastase
inhibitor caused a decrease in WW/DW and lung
water contents (P < 0.001), which, however, remained
signiﬁcantly elevated compared to controls. The HA
concentration in wet lung tissue decreased after
thrombin infusion (P < 0.001). The elastase inhibitor
counteracted this decrease (P < 0.05), but the levels of
lung HA in this group remained lower than in the
controls (P < 0.01). After thrombin treatment, the HA
concentration in dried lung tissue was lower than in
the control group (P < 0.001). The elastase inhibitor
tended to inhibit this decrease, but the difference did
not attain statistical signiﬁcance. The HA concentra-
tion in plasma was about four times higher in the
thrombin group than in the control group (P < 0.001).
This increase diminished in the presence of the elas-
tase inhibitor (P < 0.01). Thrombin treatment
effected a moderate increase of the HA concentration
in BALF (P < 0.05).
Histology
In control ratsHAwas found in the bronchial cartilage,
submucosal tissue of bronchi and bronchioles, and the
adventitia of arteries and veins. Slightly positive stain-
ing for HA was not only observed in the loose con-
nective tissue surrounding bronchi and arteries, but
also in the alveolar membranes (Figure 2A). In the
thrombin-treated animals, HA staining in the lungs
was markedly decreased and had changed into a fen-
estrated form, and HA in both the perivascular area
and alveolar wall was weakly stained. HA had partly
disappeared from the margin of vessels and cartilage,
where the perivascular spacewaswidened (Figure 2B).
Cardiac output and liver blood ﬂow
Cardiac output was well maintained until 30 min after
termination of the thrombin infusion and then pro-
gressively decreased (Figure 3). Sixty min after the
infusion cardiac output was lower (P < 0.01) and was
further decreased 90 min after termination of the
thrombin infusion (P < 0.05). Liver blood ﬂow was
well maintained until 60 min after the end of the
thrombin infusion, but was decreased at 90 min
(P < 0.05), compared to the baseline value and the
value at 60 min (Figure 3).
Discussion
Administration of thrombin resulted in pulmonary
edema, which was accompanied by a decrease in
the concentration of HA in the lungs and an increase
Table I. Effect of a leukocyte elastase inhibitor on wet weight to dry weight (WW/DW) ratio, relative lung water content, and concentration of
HA in lung tissue and plasma and bronchoalveolar lavage ﬂuid in rats with thrombin-induced pulmonary edema.
Measurements Control Thrombin Thrombin and inhibitor
WW/DW ratio 5.07 ± 0.04 (13) 7.12 ± 0.13 (21)*** 6.08 ± 0.29 (5)**,†††
Lung water content, % 80.3 ± 0.2 (13) 85.9 ± 0.3 (21)*** 83.4 ± 0.8 (5)***,†††
Lung HAWW, mg/g WW 25.7 ± 1.3 (13) 14.0 ± 0.7 (21)*** 18.9 ± 1.8 (5)**,†
Lung HADW, mg/g DW 130.3 ± 6.1 (13) 98.4 ± 4.1 (21)*** 113.2 ± 8.6 (5)
Plasma HA, ng/mL 50.5 ± 3.6 (16) 212.5 ± 30.7 (15)*** 79.5 ± 13.9 (7)*,††
BALF HA, ng/mL 16.5 ± 0.8 (8) 20.1 ± 1.1 (11)* not determined
Data are expressed as means ± SEM. Number of rats in brackets.
*P < 0.05, **P < 0.01, ***P < 0.001 versus control group.
†P < 0.05, ††P < 0.01, †††P < 0.001 compared to the animals given thrombin only.
BALF = bronchoalveolar lavage ﬂuid; DW = dry weight; HA = hyaluronan; HADW = lung HA concentration per g DW; HAWW = lung HA
levels per g WW lung tissue; WW = wet weight.
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in HA in the plasma and bronchoalveolar lavage ﬂuid,
indicating increased wash-out of HA from the lung
parenchyma. Histologically, staining for HA was
decreased in the perivascular and peribronchiolar
areas in thrombin-treated rats. To the best of our
knowledge this is the ﬁrst time that a decreased
hyaluronan content in lung tissue has been described
in a model of ARDS.
The decrease of HA in the lungs after administra-
tion of thrombin as determined both by biochemical
and histological methods contrasts with ﬁndings in
previous studies, where the concentration of lung HA
was found to be increased in similar types of lung
injury (7,8,10). One reason for this difference may be
an increased synthesis of lung HA in their studies.
Such an increase in lung HA synthesis should not
occur in our acute experiments.
The metabolic degradation of HA is carried out by
three acidhydrolases, hyaluronidase,b-N-acetylgluco-
saminidase, and b-glucuronidase (23). Rat alveolar
macrophages are known to possess HA-degrading
enzymes (24), which are activated by thrombin (25)
and myeloperoxidase (26). In a previous study, mye-
loperoxidase was increased after thrombin infusion
(27). Thus, it is conceivable that the activity of HA-
degrading enzymes might be increased in the injured
interstitium due to activation of alveolar macrophages,
which leads to further degradation of HA in the lung
tissue.
Polymorphonuclear leukocytes (15) and leukocyte
elastase (14) are associated with the development of
thrombin-induced lung injury. Toxic oxygen radi-
cals (16) and myeloperoxidase (17) produced by
thrombin-activated neutrophils (28) can directly
degrade HA. Leukocyte elastase may cleave extracel-
lular matrices such as proteoglycans, collagen, and
ﬁbrin that are bound to HA (18). Thus, HA bound to
the extracellular matrix may be released and subject to
oxygen-induced attack. This injury may lead to local
degradation of HA, facilitating the wash-out of HA
from the lung, and thus contributing to the increase in
plasma HA.
In the present study, HA-stained microsections
showed a decrease in HA in the perivascular and
peribronchiolar areas in thrombin-treated rats. The
perivascular and peribronchial location of lung HA
(5) may indicate a stabilizing function of this mole-
cule. Recent observations suggest that interstitial HA
may protect against acute inﬂammatory changes in
elastase-induced lung injury (29). Treatment with
HMW-HA attenuated sepsis-induced lung injury in
mechanically ventilated rats (30). These results indi-
cate a low lung HA content after lung injury. If HA
stabilizes lung microvessels and small airways, a
reduction of HA may diminish the strength of the
microvascular and bronchiolar barrier. Furthermore,
HA acts as an osmotic buffer and may contribute to
the water homeostasis in the interstitium. HA may
A
PA
PA
Br
Br
B
Figure 2. A: Staining of lung sections with biotin-avidin-hyaluronan-binding protein in a control rat. The red area represents hyaluronan-
speciﬁc staining. The arrow indicates the intense staining of the perivascular and peribronchiolar space. The section was counterstained with
hematoxylin (140). B: Staining of lung sections with biotin-avidin-hyaluronan-binding protein in a representative rat with thrombin-
induced pulmonary injury. The red area represents hyaluronan-speciﬁc staining. The arrow indicates the weaker staining of hyaluronan in the
perivascular and peribronchiolar space. The section was counterstained with hematoxylin (140). (PA = pulmonary artery; Br = bronchus.)
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also be of importance in the regulation of protein
transport in the interstitium. If the lung HA concen-
tration is decreased in the late phase of a thrombin-
induced lung injury, water and protein might be
extravasated from injured endothelial barriers into
the alveolar space and pass without impedance
through the interstitium, which may promote inter-
stitial and alveolar edema.
Our results in this model of ARDS are consistent
with the observations by Hällgren et al. in human
ARDS (7) and by Berg et al. in a porcine model of
injury and sepsis (31) that the HA concentration
increased in BALF and blood. However, although
these authors did not measure HA in lung tissue, they
speculated that it was increased and contributed to
pulmonary edema by immobilization of water. Some-
what in contrast, our ﬁndings suggest that lung HA
counteracts the development of pulmonary edema
and a shortage of this molecule in the lungs may
contribute to the establishment of edema. This idea
is strongly supported by the ﬁnding that administra-
tion of HMW-HA decreased the lung injury induced
by sepsis in mechanically ventilated animals (30).
A decreased concentration of HA and its major
transmembrane glycoprotein receptor, CD44, has
been shown to increase unwanted human neutrophil
elastase activity (32–34) and also to promote leuko-
cyte extravasation and formation of pro-inﬂammatory
cytokines (35,36). In the present study, the
concentration of HA in plasma was increased
90 min after thrombin infusion, at which time liver
blood ﬂow and cardiac output were decreased. This is
consistent with a recent observation in porcine peri-
tonitis (37) and in patients with ARDS (1). The
reduced hepatic blood ﬂow is probably a result of
the decreased systemic blood pressure (38) and car-
diac output, leading to a reduced capacity for hepatic
degradation of HA. A correlation between decreased
hepatic blood ﬂow and impaired liver function has
been previously observed (39). Thus, one mechanism
underlying the increased HA concentration in the
plasma may be a decreased rate of clearance by
liver endothelial cells due to a diminished liver
blood ﬂow.
To summarize, in this model of ARDS, the HA
concentration in lung was decreased, and HA staining
conﬁrmed a reduction in HA, both in the perivascular
and peribronchiolar areas. HA concentrations in
BALF and plasma were elevated, indicating increased
wash-out of HA from the lungs. A leukocyte elastase
inhibitor counteracted not only the decrease in HA in
lung tissue, but also the increase in plasma HA. The
ﬁndings suggest that a decrease in HA in the lung may
play a role in the pathogenesis of thrombin-induced
lung edema, e.g. by reducing the stability of the
microvascular and peribronchiolar barriers, and that
leukocyte elastase is associated with the decrease in
HA content in lung. An elevated plasma level of HA
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Figure 3. A: Cardiac output (CO; mL/min/kg B.W.) before (0) and 10, 30, 60, and 90 min after the end of thrombin (Thr) infusion in six rats
with thrombin-induced pulmonary injury. Data are expressed as mean ± SEM. Baseline (0 min) represents steady-state values before thrombin
infusion. ** P < 0.01 compared to the baseline values in CO. *** P < 0.001 compared to the baseline values in CO. † P < 0.05 compared to CO
measured at 60 min after thrombin infusion. B: Liver blood ﬂow (LBF; mL/min/kg liver) before (0) and 10, 30, 60, and 90 min after the end of
thrombin (Thr) infusion in eight rats with thrombin-induced pulmonary injury. Data are expressed as mean ± SEM. Baseline (0 min)
represents steady-state values before thrombin infusion. ** P < 0.01 compared to the baseline values in LBF. † P < 0.05 compared to LBF
measured at 60 min after thrombin infusion.
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may serve as an indicator of the lung damage, at least
in this ARDS model.
Acknowledgements
We wish to thank Anders Tengblad, Anette Silván,
and Anette von Malmborg for their skillful technical
help. This work was supported by the Swedish Heart–
Lung Foundation.
Declaration of interest: The authors report no
conﬂicts of interest. The authors alone are responsible
for the content and writing of the paper.
References
1. Quinn DA, Garg HG. Hyaluronan in acute lung injury. In:
Vincent JL, editor. Intensive Care Medicine. Annual update
2006. New York: Springer Science + Business Media Inc.;
2006. p. 349–58.
2. Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its
nature, distribution, functions and turnover. J Intern Med.
1997;242:27–33.
3. Laurent T. Hyaluronan research in Uppsala. Ups J Med Sci.
2007;112:123–42.
4. Boodoo S, Spannhake EW, Powell JD, Horton MR. Differ-
ential regulation of hyaluronan-induced IL-8 and IP-10 in
airway epithelial cells. Am J Physiol Lung Cell Mol Physiol.
2006;29:L479–86.
5. Nettelbladt O, Tengblad A, Hällgren R. Accumulation of
hyaluronan (hyaluronic acid) in lung tissue during experimen-
tal alveolitis parallels development of interstitial edema. Am J
Physiol. 1989;257:379–84.
6. Ormiston ML, Slaughter GRD, Deng Y, Stewart DJ,
Courtman DW. The enzymatic degradation of hyaluronan
is associated with disease progression in experimental pulmo-
nary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;
298:L148–57.
7. Hällgren R, Samuelsson T, Laurent TC, Modig J. Accumu-
lation of hyaluronan (hyaluronic acid) in the lung in adult
respiratory distress syndrome. Am Rev Respir Dis. 1989;139:
682–7.
8. Juul SE, Kinsella MG, Jackson C, Truog WE, Standaert TA,
Hodson WA. Changes in hyaluronan deposition during early
respiratory distress syndrome in premature monkeys. Pediatr
Res. 1994;35:238–43.
9. Johnsson H, Eriksson L, Jonzon A, Laurent TC, Sedin G.
Lung hyaluronan and water content in preterm and term
rabbit pups exposed to oxygen or air. Pediatr Res. 1998;44:
716–22.
10. Juul SE, Kinsella MG,Wight TN, HodsonWA. Alterations in
non-human primate (M. nemestrina) lung proteoglycans dur-
ing normal development and acute hyaline membrane disease.
Am J Respir Cell Mol Biol. 1993;8:299–310.
11. Juul SE, Kinsella MG, Truog WE, Gibson RL, Redding GJ.
Lung hyaluronan decreases during experimental group B
streptococcus (GBS) pneumonia in neonatal piglets. Am J
Respir Crit Care Med. 1996;153:1567–70.
12. RosenbaumD, Peric S, Holecek M,Ward HE. Hyaluronan in
radiation-induced lung disease in the rat. Radiation Res. 1997;
147:585–91.
13. Kropf J, Globe E, Knoch M, Lammers M, Gressner AM,
Lennartz H. The prognostic value of extracellular matrix
component concentrations in serum during treatment of a
acute respiratory distress syndrome with extracorporeal
CO2 removal. Eur J Clin Chem Clin Biochem. 1991;29:
805–12.
14. Ahn CM, Sandler H, GlassM, Saldeen T. Effect of a synthetic
leukocyte elastase inhibitor on thrombin-induced pulmonary
edema in the rat. Exp Lung Res. 1993;19:125–35.
15. Ahn CM, Sandler H, Saldeen T. Beneﬁcial effects of a
leukotriene receptor antagonist on thrombin-induced pulmo-
nary edema in the rat. Prostagladins Leukot Essent Fatty
Acids. 1995;53:433–8.
16. Moseley R, Waddington RJ, Emberg G. Degradation of
glycosaminoglycans by reactive oxygen species derived from
stimulated polymorphonuclear leukocytes. Biochim biophys
Acta. 1997;1362:221–31.
17. Green SP, Baker MS, Lowther DA. Depolymerization of
synovial ﬂuid hyaluronan (HA) by the complete myeloperox-
idase (MPO) systemmay involve the formation of a HA-MPO
ionic complex. J Rheumatol. 1990;17:1670–5.
18. Negrini D, Passi A, De Luca G, Miserochi G. Proteoglycan
involvement during development of lesional pulmonary
edema. Am J Physiol. 1998;274:L203–11.
19. Arfors K-E, Busch C, Jacobson S, Lindquist O, Malmberg P,
Rammer L, et al. Pulmonary insufﬁciency following intrave-
nous infusion of thrombin and AMCA (Tranexamic acid) in
the dog. Acta Chir Scand. 1972;138:445–52.
20. Nettelbladt O, Hällgren R. Hyaluronan (hyaluronic acid) in
bronchoalveolar lavage ﬂuid during the development of
bleomycin-induced alveolitis in the rat. Am Rev Respir Dis.
1989;140:1028–32.
21. Lundberg C, SmedegårdG. Regional differences in skin blood
ﬂow as measured by radioactive microspheres. Acta Physiol
Scand. 1981;111:491–6.
22. Schosser R, Arfors K-E, Messmer K. Mic-II—a program for
the determination of cardiac output, arterio-venous shunt and
regional blood ﬂow using the radioactive microsphere method.
Comput Programs Biomed. 1979;9:19–38.
23. Rodén L, Campbell P, Fraser JRE, Laurent TC, Pertoft H,
Thompson JN. Enzymatic pathway of hyaluronan metabolites.
CIBA Foundation Symposium. 1989;143:60–86.
24. Fiszer SB, Romman M, Brossard C, Smets P. Hyaluronic
acid degrading enzymes in rat alveolar macrophages and in
alveolar ﬂuid. Stimulation of enzyme activity after oral treat-
ment with the immunomodulator RU 41740. Biol Cell. 1988;
63:355–60.
25. Kobayashi Y, Sakamoto Y, Shibasaki M, Kimura I,
Matsuo H. Human alveolar macrophages synthesize endothe-
lins by thrombin. J Immunol. 1997;158:5442–7.
26. Grattendick K, Stuart R, Roberts E, Lincoln J, Lefkowitz SS,
Bollen A, et al. Alveolar macrophage activation by myeloper-
oxidase: a model for exacerbation of lung inﬂammation. Am J
Respir Cell Mol Biol. 2002;26:716–22.
27. Ahn CM, Sandler H, Saldeen T. A leukocyte elastase inhibitor
reduces thrombin-induced pulmonary oedema in the rat:
mechanisms of action. Pulm Pharmacol Ther. 1998;11:291–9.
28. Drake WT, Lopes NN, Fenton JW, Issekutz AC. Thrombin
enhancement of interleukin-1 and tumor necrosis factor-alpha
induced polymorphonuclear leukocyte migration. Lab Invest.
1992;67:617–27.
29. Ishibashi M, Nishida T, Murakami H, Shiraishi M,
Aritomi T, Yoshida M. The role of interstitial hyaluronan
in acute lung injury. Nippon Kyobu Shikkan Gakkai Zasshi.
1995;33S:225–30.
8 C. M. Ahn et al.
30. Liu YY, Lee CH, Dedaj R, Zhao H, Mrabat H,
Sheidlin A, et al. High-molecular-weight hyaluronan—a pos-
sible new treatment for sepsis-induced lung injury: a preclin-
ical study in mechanically ventilated rats. Crit Care. 2008;12:
R102–13.
31. Berg S, Jansson I, Hesselvik FJ, Laurent TC, Lennquist S,
Walther S. Hyaluronan: relationship to hemodynamics and
survival in porcine injury and sepsis. Crit Care Med. 1992;20:
1315–21.
32. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil
elastase in acute lung injury. Eur J Pharmacol. 2002;451:1–10.
33. Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute
lung injury. Pulm Pharmacol Ther. 2002;15:83–95.
34. Scuri M, Abraham WM. Human blocks human neutrophil
elastase (HNE)-induced airway response in sheep. Pulm
Pharmacol Ther. 2003;16:335–40.
35. Wang Q, Teder P, Judd NP, Noble PW, Doerschuk CM.
CD44 deﬁciency leads to enhanced neutrophil migration and
lung injury in Escherichia coli pneumonia in mice. Am J
Pathol. 2002;161:2219–28.
36. Johnson P, Ruffell B. CD44 and its role in inﬂammation and
inﬂammatory diseases. Inﬂamm Allergy Drug Targets. 2009;
8:208–20.
37. Rasmussen I, Lebel L, Arvidsson D, Haglund U,
Laurent TC, Gerdin B. Hepatic extraction of hyaluronic
acid in porcine peritonitis. Eur Surg Res. 1995;27:1–10.
38. Ahn CM, Sandler H, Wegener T, Saldeen T. Effect of
ibuprofen on thrombin-induced pulmonary edema in the
rat. Pulm Pharmacol. 1994;7:393–9.
39. Garrison RN, Ratcliffe DJ, Fry DE. Hepatocellular function
and nutrient blood ﬂow in experimental peritonitis. Surgery.
1982;92:713–19.
Decreased lung hyaluronan in a rat model of ARDS 9
